Maina is Director of Healthcare Investments at Imperial Innovations. She has led a number of investments in Imperial Innovations’ healthcare portfolio since joining the company in 2006, including recent investments into Psioxus Therapeutics and Cellmedica. Maina currently serves on the board of Autifony Therapeutics, Cell Medica, Ixico and Psioxus Therapeutics as well as TopiVert Pharma. She previously worked in the research and development team at Celltech (previously Oxford Glyco Sciences), at Chimeric Therapies, a cell therapy start-up based in Philadelphia and at GeneMedicine, a gene therapy company based in Houston. Maina has a BSc from the University of Texas at Austin and an MBA from the Imperial Business School. Maina is Director of Healthcare Investments at Imperial Innovations. She has led a number of investments in Imperial Innovations’ healthcare portfolio since joining the company in 2006, including recent investments into Psioxus Therapeutics and Cellmedica. Maina currently serves on the board of Autifony Therapeutics, Cell Medica, Ixico and Psioxus Therapeutics as well as TopiVert Pharma. She previously worked in the research and development team at Celltech (previously Oxford Glyco Sciences), at Chimeric Therapies, a cell therapy start-up based in Philadelphia and at GeneMedicine, a gene therapy company based in Houston. Maina has a BSc from the University of Texas at Austin and an MBA from the Imperial Business School.

fermentation